HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Increased endometrial cancer incidence prompts calls for more screening, research funding
• Does increased endometrial cancer incidence warrant more intensive screening?
• Cancer clinical trials: Not suitable for prime time John Sweetenham, MD, FRCP, FACP
• Bidirectional immuno-oncology educational program benefits community practices
• Black men achieve deeper response to abiraterone acetate for advanced prostate cancer
• Bevacizumab plus chemotherapy prolongs PFS for recurrent ovarian cancer
• Collaborative investment may expedite drug development for pediatric cancer
• Adjuvant FOLFIRINOX new standard of care for pancreatic cancer
• Adjuvant docetaxel shows benefit for gastric cancer
• Novel nivolumab combination shows efficacy for advanced solid tumors
• Benefit of first-line alectinib persists over crizotinib for ALK-positive lung cancer
• First-line atezolizumab improves PFS for advanced squamous non-small cell lung cancer
• Geriatric assessment improves oncologists’ communication with older patients
• CAR T-cell therapy bb2121 shows sustained promise for multiple myeloma
• CAR T-cell therapy benefit for pediatric leukemia dependent on prompt treatment
• Ibrutinib plus rituximab improves PFS in Waldenström’s macroglobulinemia
• Nelarabine shows ‘best ever survival data’ for children, young adults with T-cell ALL
• Long-term treatment-free remission achievable for chronic myeloid leukemia
• Targeted inhibitor induces responses for soft tissue sarcoma
• Cognitive behavioral therapy, acupuncture reduce insomnia among cancer survivors
• FDA commissioner: Greater efficiencies can unlock opportunities created by better science
• Cytoreductive nephrectomy no longer the standard for metastatic renal cell carcinoma
• Germline variant alleles may predict response to first-line abiraterone for metastatic prostate cancer
• Neoadjuvant pembrolizumab induces pathologic response in bladder cancer
• PET response after induction chemotherapy may predict esophageal cancer outcomes
• Cancer increases risk for subsequent diabetes
• US cancer deaths continue to decline
• Multigene sequencing replaces BRCA testing after breast cancer diagnosis
• Mortality risk greater for male transfusion recipients with previously pregnant donor
• Higher vitamin D levels associated with lower colorectal cancer risk for women
• FDA grants fast track designation to fimepinostat for lymphoma subtype
• FDA approves Fulphila, first Neulasta biosimilar, to prevent infection during cancer treatment
• FDA grants priority review to Hemlibra for hemophilia A without factor VIII inhibitors
• FDA grants priority review to larotrectinib for certain solid tumors
• FDA grants priority review to Promacta for frontline treatment of severe aplastic anemia
• FDA breakthrough therapy designation not associated with improved safety, efficacy
• 11 institutions join AACR Project GENIE Consortium
• Radiation oncologist to serve as American Radium Society’s president-elect